Meyka Pro banner
Sanara MedTech Inc.

Sanara MedTech Inc. Fundamental Analysis (NASDAQ: SMTI)

SMTI●NASDAQ
HealthcareMedical - Instruments & Supplies
$32.55
$0.12(0.37%)
U.S. Market opens in 51h 34m

Sanara MedTech Inc. Fundamental Analysis (NASDAQ: SMTI)

Sanara MedTech Inc. (NASDAQ: SMTI) shows moderate financial fundamentals with a PE ratio of -91.49, profit margin of -2.69%, and ROE of -42.22%. The company generates $0.1B in annual revenue with strong year-over-year growth of 18.97%.

Key Strengths

PEG Ratio-0.77
Current Ratio2.24

Areas of Concern

ROE-42.22%
Operating Margin7.20%
We analyze SMTI's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -14.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-14.0/100

We analyze SMTI's fundamental strength across five key dimensions:

Efficiency Score

Weak

SMTI struggles to generate sufficient returns from assets.

ROA > 10%
-4.17%

Valuation Score

Excellent

SMTI trades at attractive valuation levels.

PE < 25
-91.49
PEG Ratio < 2
-0.77

Growth Score

Moderate

SMTI shows steady but slowing expansion.

Revenue Growth > 5%
18.97%
EPS Growth > 10%
-2.82%

Financial Health Score

Moderate

SMTI shows balanced financial health with some risks.

Debt/Equity < 1
6.35
Current Ratio > 1
2.24

Profitability Score

Weak

SMTI struggles to sustain strong margins.

ROE > 15%
-4222.12%
Net Margin ≥ 15%
-2.69%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is SMTI Expensive or Cheap?

P/E Ratio

SMTI trades at -91.49 times earnings. This suggests potential undervaluation.

-91.49

PEG Ratio

When adjusting for growth, SMTI's PEG of -0.77 indicates potential undervaluation.

-0.77

Price to Book

The market values Sanara MedTech Inc. at 37.46 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

37.46

EV/EBITDA

Enterprise value stands at 36.57 times EBITDA. This signals the market has high growth expectations.

36.57

How Well Does SMTI Make Money?

Net Profit Margin

For every $100 in sales, Sanara MedTech Inc. keeps $-2.69 as profit after all expenses.

-2.69%

Operating Margin

Core operations generate 7.20 in profit for every $100 in revenue, before interest and taxes.

7.20%

ROE

Management delivers $-42.22 in profit for every $100 of shareholder equity.

-42.22%

ROA

Sanara MedTech Inc. generates $-4.17 in profit for every $100 in assets, demonstrating efficient asset deployment.

-4.17%

Following the Money - Real Cash Generation

Operating Cash Flow

Sanara MedTech Inc. generates limited operating cash flow of $7.76M, signaling weaker underlying cash strength.

$7.76M

Free Cash Flow

Sanara MedTech Inc. produces free cash flow of $7.62M, offering steady but limited capital for shareholder returns and expansion.

$7.62M

FCF Per Share

Each share generates $0.83 in free cash annually.

$0.83

FCF Yield

SMTI converts 2.44% of its market value into free cash.

2.44%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-91.49

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.77

vs 25 benchmark

P/B Ratio

Price to book value ratio

37.46

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.68

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

6.35

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.24

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.42

vs 25 benchmark

ROA

Return on assets percentage

-0.04

vs 25 benchmark

ROCE

Return on capital employed

0.14

vs 25 benchmark

How SMTI Stacks Against Its Sector Peers

MetricSMTI ValueSector AveragePerformance
P/E Ratio-91.4930.24 Better (Cheaper)
ROE-42.22%540.00% Weak
Net Margin-2.69%-2322.00% (disorted) Weak
Debt/Equity6.350.08 Weak (High Leverage)
Current Ratio2.245.59 Strong Liquidity
ROA-4.17%-17516.00% (disorted) Weak

SMTI outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sanara MedTech Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

339.96%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-473.41%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

211.87%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ